Filing Details
- Accession Number:
- 0001125345-24-000063
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-08 16:14:52
- Reporting Period:
- 2024-03-06
- Accepted Time:
- 2024-03-08 16:14:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1125345 | Macrogenics Inc | MGNX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1706903 | Stuart Jeffrey Peters | 9704 Medical Center Drive Rockville MD 20850 | Senior Vp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-06 | 10,875 | $11.50 | 19,770 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-03-06 | 8,750 | $10.15 | 28,520 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-03-06 | 19,625 | $21.50 | 8,895 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee stock option (right to buy) | Disposition | 2024-03-06 | 10,875 | $11.50 | 10,875 | $11.50 |
| Common Stock | Employee stock option (right to buy) | Disposition | 2024-03-06 | 8,750 | $10.15 | 8,750 | $10.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2030-02-20 | No | 4 | M | Direct | |
| 39,375 | 2032-02-22 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
- 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
Billionaire Hedge Funds
